Brainsway (NASDAQ:BWAY) Price Target Raised to $19.00

Brainsway (NASDAQ:BWAY) had its price objective upped by HC Wainwright from $17.00 to $19.00 in a report released on Monday, MarketBeat.com reports. The firm currently has a buy rating on the stock. HC Wainwright also issued estimates for Brainsway’s Q3 2026 earnings at $0.12 EPS, FY2026 earnings at $0.38 EPS, Q2 2027 earnings at $0.18 EPS, Q3 2027 earnings at $0.20 EPS, Q4 2027 earnings at $0.22 EPS and FY2027 earnings at $0.75 EPS.

BWAY has been the subject of several other research reports. Zacks Research lowered Brainsway from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 11th. BTIG Research upped their price objective on shares of Brainsway from $18.00 to $20.00 and gave the company a “buy” rating in a report on Wednesday, August 12th. New Street Research reiterated a “buy” rating on shares of Brainsway in a research report on Friday, July 24th. Weiss Ratings downgraded shares of Brainsway from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Wednesday, August 19th. Finally, LADENBURG THALM/SH SH boosted their price target on shares of Brainsway from $18.00 to $18.80 and gave the company a “buy” rating in a research report on Thursday, August 13th. Five research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat, Brainsway has an average rating of “Moderate Buy” and a consensus target price of $18.20.

Brainsway Price Performance

NASDAQ:BWAY opened at $14.28 on Monday. The business has a fifty day simple moving average of $15.21 and a two-hundred day simple moving average of $14.67. Brainsway has a 1 year low of $7.14 and a 1 year high of $17.40. The company has a market capitalization of $573.91 million, a P/E ratio of 32.46 and a beta of 1.25.

Brainsway (NASDAQ:BWAY) last issued its earnings results on Wednesday, August 12th. The company reported $0.14 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.10 by $0.04. Brainsway had a return on equity of 12.74% and a net margin of 15.65%.The firm had revenue of $17.11 million for the quarter, compared to analyst estimates of $16.54 million. As a group, analysts anticipate that Brainsway will post 0.33 earnings per share for the current year.

Institutional Trading of Brainsway

A number of hedge funds and other institutional investors have recently made changes to their positions in BWAY. Masters Capital Management LLC raised its stake in shares of Brainsway by 65.0% during the 1st quarter. Masters Capital Management LLC now owns 1,650,000 shares of the company’s stock valued at $21,928,000 after purchasing an additional 650,000 shares during the period. Renaissance Technologies LLC boosted its stake in Brainsway by 87.2% in the 1st quarter. Renaissance Technologies LLC now owns 518,420 shares of the company’s stock worth $6,890,000 after purchasing an additional 241,560 shares during the period. Y.D. More Investments Ltd boosted its stake in Brainsway by 136.6% in the 1st quarter. Y.D. More Investments Ltd now owns 272,004 shares of the company’s stock worth $3,615,000 after purchasing an additional 157,042 shares during the period. Sei Investments Co. grew its holdings in Brainsway by 262.5% during the 1st quarter. Sei Investments Co. now owns 226,378 shares of the company’s stock valued at $3,009,000 after buying an additional 163,925 shares in the last quarter. Finally, ARK Investment Management LLC purchased a new position in Brainsway during the 4th quarter valued at about $2,422,000. 30.11% of the stock is currently owned by institutional investors.

Brainsway Company Profile

Brainsway Ltd is a medical device company specializing in non-invasive neuromodulation therapies. Publicly traded on the NASDAQ under the symbol BWAY, the company develops and commercializes deep transcranial magnetic stimulation (Deep TMS) systems designed to treat a range of neuropsychiatric and neurological disorders. Brainsway’s technology aims to offer an alternative or complement to traditional pharmacological therapies by targeting precise brain regions with its patented coil designs.

The company’s flagship Deep TMS platform utilizes proprietary H-coil arrays engineered to reach deeper cortical structures than conventional TMS devices.